Asymptomatic Severe Aortic Stenosis: What the Exercise Test Changed
A single patient whose aortic stenosis has produced no symptoms he's noticed, and one finding on formal testing that changes how seriously “no symptoms” should be taken.
R.C., a 74-year-old man, spent thirty-eight years as an insurance adjuster before retiring, a career he says trained him to distrust anything that looks fine on the surface without checking the paperwork underneath — an instinct that turned out to matter more than he expected when a routine murmur workup led to an echocardiogram he wasn't anticipating. He walks two miles most mornings, plays golf weekly, and by his own account has noticed nothing wrong.
The echocardiogram showed severe aortic stenosis — an aortic valve area of 0.9cm², a mean gradient of 46mmHg — with preserved ejection fraction and no history of chest pain, breathlessness, or fainting to suggest the valve has caught up with him yet. Because true asymptomatic status can be hard to confirm by history alone in an active, motivated person who may be unconsciously limiting himself, an exercise treadmill test was performed, and it showed an abnormal blood pressure response — a fall in systolic pressure of more than 10mmHg below baseline with exertion, which is the specific threshold guidelines name, rather than merely a blunted rise.
Current guidelines have moved toward earlier intervention in asymptomatic severe AS specifically because outcomes data show real risk of sudden cardiac events accumulating even before symptoms become apparent, and a fall in exercise blood pressure is one of the findings that makes intervention reasonable in a truly asymptomatic patient rather than mandatory — it carries a moderate-strength recommendation, not the force symptoms or a reduced ejection fraction would. That still leaves how — TAVR and SAVR are both now realistic options across his age range, with genuinely different tradeoffs in recovery, procedural risk, and how much is actually known yet about how each holds up decades out.
Whether to act now, and which procedure if so
His exercise test changes this from watchful waiting to an intervention conversation. He believes he's asymptomatic, and by history he is, but a fall in exercise blood pressure is exactly the kind of objective finding current guidelines treat as unmasking risk a self-report can miss — people gradually limit themselves without noticing. I don't think we should keep surveilling him on the strength of a symptom history that formal testing has already called into question.
I agree it's time to act, and at his age I'd lean toward surgical replacement rather than transcatheter. He's low surgical risk, which is exactly the profile where SAVR's decades of durability data still carries real weight — he could reasonably live well over another decade, and I'd rather give him a valve with a longer track record for that horizon than one where the newest data is still maturing.
I'd push back gently on defaulting to surgery at his age. The low-risk TAVR trials enrolled patients very much like him and showed comparable outcomes to surgery with a substantially easier recovery, and the durability gap has been narrowing with each generation of valve, not staying fixed. I don't think this should be decided by his age alone — it deserves a real Heart Team discussion of his specific anatomy and his own priorities about recovery time versus long-term certainty.
Whichever procedure he ends up with, the antithrombotic regimen that follows isn't identical between the two, and it belongs in this conversation rather than being settled afterward as an afterthought. Contemporary trial data has moved TAVR away from routine dual antiplatelet therapy toward single antiplatelet therapy alone in patients without a separate anticoagulation indication — the added bleeding risk from dual therapy wasn't matched by a reduction in thrombotic events. A surgical bioprosthetic valve, by contrast, still carries a genuine, if debated, case for a short warfarin course in the first three months, when leaflet thrombosis risk is highest. Neither path is more demanding long-term, but they're different regimens with different early risks, and that's worth weighing alongside recovery time and durability data, not decided by default once the procedure itself is chosen.
Agreed: intervention rather than continued surveillance, based on the abnormal exercise blood pressure response. Heart Team referral placed today to determine TAVR versus SAVR based on his specific anatomy and preferences, rather than deciding that question at this visit.
He proceeds toward a transcatheter approach, prioritizing the shorter recovery given his active baseline lifestyle.
He proceeds toward surgical replacement, prioritizing the more mature durability data for his likely remaining life expectancy.
The surgeon and interventional cardiologist never resolved which procedure genuinely serves a low-risk 74-year-old better — both cited real, defensible evidence for their position — and the group agreed that was itself the reason to send the actual choice to a dedicated Heart Team discussion rather than settle it in this conversation.